Our results confirmed that rs6713088, rs843645, rs843711 and rs843706 were significantly increased liver cancer risk, but rs1682111, rs843720 and haplotypes (ATATCGCC and CG) were significantly decreased liver cancer risk in a Han Chinese population.
Our results confirmed that rs6713088, rs843645, rs843711 and rs843706 were significantly increased liver cancer risk, but rs1682111, rs843720 and haplotypes (ATATCGCC and CG) were significantly decreased liver cancer risk in a Han Chinese population.
Rs1682111 and rs843720 play a protective role in the additive model (rs1682111: OR = 0.69, 95% CI: 0.52-0.93, p = 0.01; rs843720: OR = 0.73, 95% CI: 0.54-0.98, p = 0.04).While rs843645 G allele increased the risk of cirrhosis developed into liver cancer under the additive model (OR = 1.42, 95% CI: 1.02-2.00, p = 0.04).The haplotype analysis detected that "ATATCGCC" decreased the risk of cirrhosis developed into liver cancer (OR = 0.69, 95% CI: 0.51-0.92, 95% CI: p = 0.013); however, "TGAGCGTC" increased the risk of cirrhosis developed into liver cancer (OR = 1.48, 95% CI: 1.04-2.10, p = 0.027).
In addition, we found that rs1682111 and rs17045754 were associated with the risk of BC and correlated with recurrence, and that rs6713088 correlated with tumor size.
Our results confirmed that rs6713088, rs843645, rs843711 and rs843706 were significantly increased liver cancer risk, but rs1682111, rs843720 and haplotypes (ATATCGCC and CG) were significantly decreased liver cancer risk in a Han Chinese population.
Rs1682111 and rs843720 play a protective role in the additive model (rs1682111: OR = 0.69, 95% CI: 0.52-0.93, p = 0.01; rs843720: OR = 0.73, 95% CI: 0.54-0.98, p = 0.04).While rs843645 G allele increased the risk of cirrhosis developed into liver cancer under the additive model (OR = 1.42, 95% CI: 1.02-2.00, p = 0.04).The haplotype analysis detected that "ATATCGCC" decreased the risk of cirrhosis developed into liver cancer (OR = 0.69, 95% CI: 0.51-0.92, 95% CI: p = 0.013); however, "TGAGCGTC" increased the risk of cirrhosis developed into liver cancer (OR = 1.48, 95% CI: 1.04-2.10, p = 0.027).
In addition, we found that rs1682111 and rs17045754 were associated with the risk of BC and correlated with recurrence, and that rs6713088 correlated with tumor size.
Rs1682111 and rs843720 play a protective role in the additive model (rs1682111: OR = 0.69, 95% CI: 0.52-0.93, p = 0.01; rs843720: OR = 0.73, 95% CI: 0.54-0.98, p = 0.04).While rs843645 G allele increased the risk of cirrhosis developed into liver cancer under the additive model (OR = 1.42, 95% CI: 1.02-2.00, p = 0.04).The haplotype analysis detected that "ATATCGCC" decreased the risk of cirrhosis developed into liver cancer (OR = 0.69, 95% CI: 0.51-0.92, 95% CI: p = 0.013); however, "TGAGCGTC" increased the risk of cirrhosis developed into liver cancer (OR = 1.48, 95% CI: 1.04-2.10, p = 0.027).
Taking a genome-wide association study approach, we identified inherited genetic variations in ACYP2 associated with cisplatin-related ototoxicity (rs1872328: P = 3.9 × 10(-8), hazard ratio = 4.5) in 238 children with newly diagnosed brain tumors, with independent replication in 68 similarly treated children.
The variant rs1872328 in the ACYP2 gene was recently identified as a risk factor for the development of cisplatin-induced ototoxicity in children with brain tumors.
Rs1682111 and rs843720 play a protective role in the additive model (rs1682111: OR = 0.69, 95% CI: 0.52-0.93, p = 0.01; rs843720: OR = 0.73, 95% CI: 0.54-0.98, p = 0.04).While rs843645 G allele increased the risk of cirrhosis developed into liver cancer under the additive model (OR = 1.42, 95% CI: 1.02-2.00, p = 0.04).The haplotype analysis detected that "ATATCGCC" decreased the risk of cirrhosis developed into liver cancer (OR = 0.69, 95% CI: 0.51-0.92, 95% CI: p = 0.013); however, "TGAGCGTC" increased the risk of cirrhosis developed into liver cancer (OR = 1.48, 95% CI: 1.04-2.10, p = 0.027).
Rs1682111 and rs843720 play a protective role in the additive model (rs1682111: OR = 0.69, 95% CI: 0.52-0.93, p = 0.01; rs843720: OR = 0.73, 95% CI: 0.54-0.98, p = 0.04).While rs843645 G allele increased the risk of cirrhosis developed into liver cancer under the additive model (OR = 1.42, 95% CI: 1.02-2.00, p = 0.04).The haplotype analysis detected that "ATATCGCC" decreased the risk of cirrhosis developed into liver cancer (OR = 0.69, 95% CI: 0.51-0.92, 95% CI: p = 0.013); however, "TGAGCGTC" increased the risk of cirrhosis developed into liver cancer (OR = 1.48, 95% CI: 1.04-2.10, p = 0.027).
We found that rs6713088 (G allele: odds ratio [OR] = 1.27, 95% confidence interval [CI]: 1.07-1.52, <i>P</i> = 0.007; GG vs. CC: OR = 1.49, 95% CI: 1.02-2.1, <i>P</i> = 0.038), rs843711 (T allele: OR = 1.29, 95% CI: 1.09-1.54, <i>P</i> = 0.004; TT vs. CC: OR = 1.62, 95% CI: 1.13-2.31, <i>P</i> = 0.008), rs843706 (A allele: OR = 1.30, 95% CI: 1.09-1.55, <i>P</i> = 0.003; AA vs. CC: OR = 1.62, 95% CI: 1.13-2.31, <i>P</i> = 0.008), and rs843645 (GG vs. AG: OR = 1.40, 95% CI: 1.07-1.82, <i>P</i> = 0.014) were associated with an increased risk of liver cancer.
Rs1682111 and rs843720 play a protective role in the additive model (rs1682111: OR = 0.69, 95% CI: 0.52-0.93, p = 0.01; rs843720: OR = 0.73, 95% CI: 0.54-0.98, p = 0.04).While rs843645 G allele increased the risk of cirrhosis developed into liver cancer under the additive model (OR = 1.42, 95% CI: 1.02-2.00, p = 0.04).The haplotype analysis detected that "ATATCGCC" decreased the risk of cirrhosis developed into liver cancer (OR = 0.69, 95% CI: 0.51-0.92, 95% CI: p = 0.013); however, "TGAGCGTC" increased the risk of cirrhosis developed into liver cancer (OR = 1.48, 95% CI: 1.04-2.10, p = 0.027).
We found that rs6713088 (G allele: odds ratio [OR] = 1.27, 95% confidence interval [CI]: 1.07-1.52, <i>P</i> = 0.007; GG vs. CC: OR = 1.49, 95% CI: 1.02-2.1, <i>P</i> = 0.038), rs843711 (T allele: OR = 1.29, 95% CI: 1.09-1.54, <i>P</i> = 0.004; TT vs. CC: OR = 1.62, 95% CI: 1.13-2.31, <i>P</i> = 0.008), rs843706 (A allele: OR = 1.30, 95% CI: 1.09-1.55, <i>P</i> = 0.003; AA vs. CC: OR = 1.62, 95% CI: 1.13-2.31, <i>P</i> = 0.008), and rs843645 (GG vs. AG: OR = 1.40, 95% CI: 1.07-1.82, <i>P</i> = 0.014) were associated with an increased risk of liver cancer.
We found that rs6713088 (G allele: odds ratio [OR] = 1.27, 95% confidence interval [CI]: 1.07-1.52, <i>P</i> = 0.007; GG vs. CC: OR = 1.49, 95% CI: 1.02-2.1, <i>P</i> = 0.038), rs843711 (T allele: OR = 1.29, 95% CI: 1.09-1.54, <i>P</i> = 0.004; TT vs. CC: OR = 1.62, 95% CI: 1.13-2.31, <i>P</i> = 0.008), rs843706 (A allele: OR = 1.30, 95% CI: 1.09-1.55, <i>P</i> = 0.003; AA vs. CC: OR = 1.62, 95% CI: 1.13-2.31, <i>P</i> = 0.008), and rs843645 (GG vs. AG: OR = 1.40, 95% CI: 1.07-1.82, <i>P</i> = 0.014) were associated with an increased risk of liver cancer.
In the allele model, ACYP2 rs843720 was protection against the occurrence of cirrhosis developed into liver cancer (OR = 0.76, 95% CI: 0.58-0.99, p = 0.04).
Our results confirmed that rs6713088, rs843645, rs843711 and rs843706 were significantly increased liver cancer risk, but rs1682111, rs843720 and haplotypes (ATATCGCC and CG) were significantly decreased liver cancer risk in a Han Chinese population.
Our results confirmed that rs6713088, rs843645, rs843711 and rs843706 were significantly increased liver cancer risk, but rs1682111, rs843720 and haplotypes (ATATCGCC and CG) were significantly decreased liver cancer risk in a Han Chinese population.